JD.com (JD) stock slipped early Thursday despite the Chinese e-commerce company reporting better-than-expected third-quarter earnings. Revenue grew 5.1% but came in just below consensus.
↑ XJD said that it earned an adjusted 8.68 yuan per American depositary share (ADS), or $1.20, on sales of 260.39 billion yuan, or $36 billion, for the September-ended quarter. Analysts polled by FactSet projected the Beijing-based company would post adjusted earnings of 7.57 yuan per ADS on sales of 260.43 yuan. Other consensus estimates placed expectations for JD's revenue at 261.45 billion yuan.
Sales growth accelerated from Q2's 1.2%. Third quarter earnings per ADS increased 29.5%.
"We saw an uptick in our topline growth, as well as healthy profitability in the third quarter, as overall consumer sentiment continued to brighten," JD Chief Executive Sandy Xu said in a news release.
On the stock market today, JD stock is down 2% at 35 in premarket action.
Overall, JD stock is ahead 27% year-to-date. But shares have bounced around as investors debate how well stimulus efforts from the Chinese government can restart overall economic growth. Donald Trump's U.S. presidential victory compounds that concern, with the threat of massive new tariffs vs. China.
Shares surged nearly 50% in the month of September but leveled off in October and are down 12% so far in November. JD had tumbled 6.9% this week, dropping below the 50-day and 10-week lines.
Coming into the report, JD had an IBD Composite Rating of 85 out of a best-possible 99, according to IBD Stock Checkup. The score combines five separate proprietary ratings into one rating. The best growth stocks have a Composite Rating of 90 or better.
Further, JD's IBD Relative Strength Rating was 87 out of 99. The RS Rating means that JD has outperformed 88% of all stocks in IBD's database over the past 12 months.
YOU MAY ALSO LIKE:
Sea Ltd. Stock Surges As 31% Revenue Growth Shows E-Commerce Strength
IBD Live: Learn And Analyze Growth Stocks With The Pros
Get Timely Buy & Sell Alerts With IBD Leaderboard
Top Growth Stocks To Buy And Watch
Learn How To Time The Market With IBD's ETF Market Strategy
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.